Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3340376

CC(=O)Nc1cccc(-c2ccc(OCCNC3CCC(C)(C)CC3)cc2)c1.O=C(O)C(F)(F)F

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
BRAF P15056 2/20 0.43
FYN P06241 1/20 0.42
KDM4E B2RXH2 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
BACE1 P56817 1/20 0.41
PTGIR P43119 3/20 0.40
MAPT P10636 1/20 0.39
NPC1 O15118 1/20 0.39
RARB P10826 1/20 0.39
RARG P13631 1/20 0.39
AVPR1A P37288 1/20 0.39
CYP17A1 P05093 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12651251 0.94 ALDH1A1 (0.49) ALDH1A1BRAFFYNKDM4ETDP1
Trifluoroacetic Acid SCHEMBL1790344 0.91 ALDH1A1 (0.47) ALDH1A1KDM4ETDP1KMT2AMEN1
Trifluoroacetic Acid SCHEMBL3338284 0.88 DPP4 (0.46) ALDH1A1KDM4ETDP1KMT2AMEN1
SCHEMBL3340378 0.85 ALDH1A1 (0.43) ALDH1A1KDM4ETDP1MAPTNPC1
SCHEMBL12651466 0.85 ALDH1A1 (0.49) ALDH1A1KDM4ETDP1KMT2AMEN1
Trifluoroacetic Acid SCHEMBL3343094 0.82 ALDH1A1 (0.45) ALDH1A1KDM4ETDP1KMT2AMEN1
Trifluoroacetic Acid SCHEMBL3340913 0.81 ALDH1A1 (0.44) ALDH1A1KDM4ETDP1KMT2AMEN1
SCHEMBL12651149 0.79 KDM1A (0.45) ALDH1A1KDM4ERARBRARG
SCHEMBL1789424 0.78 ALDH1A1 (0.50) ALDH1A1FYNKDM4ETDP1RARB
Trifluoroacetic Acid SCHEMBL3042666 0.78 ALDH1A1 (0.42) ALDH1A1KDM4ETDP1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors GLAXOSMITHKLINE LLC 2014-10-30 US disclosed
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS IGNAR DIANE MICHELE 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS OPRL1, OPRD1, OPRK1 ALDH1A1 4254/4885BRAF 4602/4885FYN 4593/4885
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors OPRL1, OPRM1, OPRK1 ALDH1A1 3500/4885BRAF 4575/4885FYN 2651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.